Trial Profile
A Pilot Study Of Open-Label Fixed Dose Combination Zidovudine/Lamivudine/Abacavir In HIV-Infected Persons With Tuberculosis In Moshi, Tanzania; Tuberculosis And HIV Immune Reconstitution Syndrome Trial (THIRST).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Lamivudine/zidovudine/abacavir (Primary) ; Antituberculars
- Indications HIV infections; HIV-1 infections; Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms THIRST
- 27 Feb 2009 New trial record